Pharmacokinetic Study of the Low-Molecular-Weight Heparin Fraxiparin in Patients with Nephrotic Syndrome
| Autor: | M Aiach, M Alhenc-Gelas, J Rossert, C Jacquot |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male medicine.medical_specialty Nephrotic Syndrome Time Factors medicine.drug_class Low molecular weight heparin Subcutaneous injection Pharmacokinetics Internal medicine Humans Medicine Aged Hemostasis business.industry Anticoagulant Anticoagulants Nadroparin Glomerulonephritis Heparin Heparin Low-Molecular-Weight Middle Aged medicine.disease Endocrinology Female business Nephrotic syndrome medicine.drug |
| Zdroj: | Nephron. 71:149-152 |
| ISSN: | 2235-3186 1660-8151 |
| DOI: | 10.1159/000188703 |
| Popis: | We studied the pharmacokinetics of the low-molecular-weight heparin (LMWH) Fraxiparin in 6 patients with the nephrotic syndrome. Maximal plasma anti-Xa activity was obtained 5 h after a subcutaneous injection of 60 IU anti-Xa/kg. Anti-Xa activity was no longer detectable 24 h postinjection. These results are similar to those obtained with the same dosage in other clinical settings. The biological response to a daily subcutaneous injection of 60 IU anti-Xa/kg was studied for 8 days. No cumulative effect was observed. All the patients had an abnormal activation state of hemostasis mechanisms before treatment, as shown by high prothrombin fragment 1 + 2 and D-dimer levels, which were not decreased by Fraxiparin. It remains to be determined whether a higher dosage of LMWH might attenuate the hypercoagulability in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|